Latest tools for COVID-19 Omicron variant research
January 10, 2022
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection [...]
January 10, 2022
Company has already booked multiple orders and established COEs in three major geographies REDWOOD CITY, Calif. -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced Broad Commercial Release of its Proteograph Product Suite and the launch of its Centers of Excellence program. The Proteograph Product Suite [...]
Agilent Presents Thought Leader Award to Professor Jason Kovacic
January 10, 2022
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today announced that Professor Jason Kovacic has been selected to receive a prestigious Agilent Thought Leader Award. Professor Kovacic is being recognized for his influential research on cardiovascular disease—specifically the pathobiology of vascular diseases, [...]
January 10, 2022
-- Reveals Plug and Play, Low Cost, No Scar, Scalable Enzymatic Synthesis 3.0 -- -- Partners with PacBio, Singular Genomics Enabling New Sequencing Platforms -- SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it [...]
January 10, 2022
Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to their studies REDWOOD CITY, Calif. and HUNTSVILLE, Ala. and FRAMINGHAM, Mass. -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics; SCIEX, a global leader in life science analytical [...]
January 10, 2022
Amsterdam, the Netherlands – LUMICKS, a next generation life science tools provider, today announced that two major centers of excellence in cancer immunology have adopted LUMICKS’ z-Movi® Cell Avidity Analyzer instrument. The first placement is at Fred Hutchinson Cancer Research Center (“Fred Hutch”) in Seattle, Washington, USA, a leading research institute dedicated to the eradication of cancer. The instrument [...]
January 10, 2022
(Peabody, MA) - A new Scanning Electron Microscope (SEM) from JEOL answers the need for faster and easier acquisition of both SEM images and EDS data analysis, especially suited for repetitive operations and quality control. JEOL, the global leader in the development of cutting-edge Electron Microscopes for materials characterization and analysis, introduces its latest SEM, the [...]
Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business
January 10, 2022
BOSTON and LAUSANNE, Switzerland -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the hiring of Peter Casasanto as Chief BioPharma Officer and Abhimanyu (Abhi) Verma as Chief Technology Officer. The additions are part of [...]
NanoString Announces Commercial Leadership Transition
January 9, 2022
Chad Brown to Retire Following More than Four Successful Years as SVP, Sales & Marketing Genomics and Diagnostics Veteran John D. Gerace Appointed as Chief Commercial Officer SEATTLE -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced a commercial leadership transition. Chad Brown, who has [...]
January 9, 2022
Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum BRANFORD, Conn. -- IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the full year 2021. Total revenue for 2021 is expected to be in the range of $17.0 to $17.2 million, representing an increase of [...]

